PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t working, but it’s not without risk.

A clinic in Arapahoe County is exploring new ways to help patients by offering ketamine-assisted psychotherapy.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Exploring new treatment avenues has become crucial as mental health challenges such as depression and PTSD continue impacting a significant number of individuals globally. Traditional therapies might not work for everyone,

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of research suggesting it can be especially effective against types

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A new study has found small amounts of liquid ketamine administered in a clinical setting can significantly reduce symptoms of post-traumatic stress disorder, with fewer side effects.

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year than those who reported no past-year drug use.